Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Brian Mcgee Insider Profile
4 Followers
Brian Mcgee, Director at Generex Biotechnology, holds 70.00 shares in Generex Biotechnology (Ticker: GNBTQ).
Brian Mcgee Generex Biotechnology (GNBTQ)Director
Generex Biotechnology (GNBTQ)
Director
Not Ranked
Brian Mcgee has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Brian Mcgee does not currently own shares as a corporate insider.
A breakdown of Brian Mcgee's holdings
Insider Roles
Brian Mcgee does not currently hold a role as a corporate insider.
Roles that Brian Mcgee holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Brian Mcgee
Brian Mcgee's Trading History
List of latest transactions for each holding click on a transaction to see Brian Mcgee's performance on stock
You May Also Like
Brian Mcgee insider profile FAQ
What is the percentage of profitable transactions made by Brian Mcgee?
The percentage of profitable transactions made by Brian Mcgee is ―.
What is the average return per transaction made by Brian Mcgee?
The average return per transaction made by Brian Mcgee is ―.
What stocks does Brian Mcgee hold?
Brian Mcgee holds: GNBTQ stocks.
What was Brian Mcgee’s latest transaction?
Brian Mcgee latest transaction was an Uninformative Buy of ―.
What was Brian Mcgee's most profitable transaction?
Brian Mcgee’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Brian Mcgee's role in Generex Biotechnology?
Brian Mcgee's role in Generex Biotechnology is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.